典型支气管类癌术后生存预后模型的外部验证
本研究在7个中心240例手术切除的典型支气管类癌患者中,外部验证欧洲胸外科医师协会神经内分泌肿瘤工作组开发的5年总生存预后模型。中位随访42个月,5年总生存率为94.2%,风险分级A至D的生存率显著递减(p=0.004),且该模型分层优于传统TNM分期。
要点
- 该预后模型在独立队列中验证有效,风险分级A至D的5年生存率显著递减。
- 模型分层能力优于传统TNM分期,TNM I、II、III期患者总生存无差异(p=0.94)。
- 模型可用于患者预后咨询及高危患者治疗决策。
核心结论
- 该生存预后模型在独立队列中验证有效,且分层能力优于传统TNM分期。
研究设计与样本
- 回顾性收集7个中心2000至2015年240例连续手术切除的典型支气管类癌患者数据。
- 使用男性、年龄、既往恶性肿瘤、ECOG体能状态、外周肿瘤、TNM分期计算风险分级A至D。
主要发现
- 中位随访42个月,5年总生存率为94.2%(95%CI:90.2%至98.2%),240例中15例死亡。
- 风险分级A至D的5年生存率分别为100%(95%CI:100%至100%)、96.3%(95%CI:88.6%至98.8%)、86.7%(95%CI:63.0%至95.7%)、33.3%(95%CI:0.9%至77.4%),递减趋势显著(p=0.004)。
- 以临床分期替代TNM分期计算风险分级时,生存差异仍显著(p=0.006)。
- TNM分期I、II、III期患者总生存无差异(p=0.94)。
临床怎么用
- 可用于向患者咨询手术治疗的预后结局。
- 可用于识别高危患者并制定个体化治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: This study aimed to assess the reliability and the validity of a prognostic model of survival recently developed by the European Society of Thoracic Surgery Neuroendocrine Tumor Working Group to predict 5-year overall survival after surgical resection of pulmonary typical carcinoid. METHODS: We retrospectively collected data on 240 consecutive patients (164 men, 76 women; median age, 58 years [interquartile range, 47 to 68]) who underwent curative lung resection for pulmonary typical carcinoid in seven centers between 2000 and 2015. For each patient, we calculated the corresponding risk class (A, B, C, D) using the following variables: male, age, previous malignancy, Eastern Cooperative Oncology Group performance status, peripheral tumor, TNM stage. Kaplan-Meier method, and Cox proportional hazards model were used for the statistical analysis. RESULTS: During a median follow-up of 42 months (interquartile range, 11 to 84), the 5-year overall survival was 94.2% (95% confidence interval [CI]: 90.2% to 98.2%); 15 of 240 patients died. A significantly decreasing rate of survival was observed from class A to class D (p = 0.004) with rates of 100% (95% CI: 100% to 100%), 96.3% (95% CI: 88.6% to 98.8%), 86.7% (95% CI: 63.0% to 95.7%), and 33.3% (95% CI: 0.9% to 77.4%), respectively, for class A, B, C, and D. This difference persisted also using clinical stage as a variable in the risk class calculation (p = 0.006). No differences were observed in term of overall survival among TNM stage I, II, and III patients (p = 0.94). CONCLUSIONS: This prognostic model of survival is easily applicable, it is validated by our independent cohort, and it appears to stratify better than the traditional TNM staging. Therefore, it may be useful in counseling patients about their outcomes from surgical treatment and in tailoring treatment for high-risk patients.
引用
- Cattoni M, Vallières E, Brown LM, et al. External Validation of a Prognostic Model of Survival for Resected Typical Bronchial Carcinoids. Ann Thorac Surg. 2017. PMID: 28821334. doi:10.1016/j.athoracsur.2017.05.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。